PUBLISHER: The Business Research Company | PRODUCT CODE: 1720752
PUBLISHER: The Business Research Company | PRODUCT CODE: 1720752
Choroidal Neovascularization Global Market Report 2025
Choroidal neovascularization (CNV) is the abnormal growth of blood vessels in the choroid layer of the eye, often extending into the retina. These newly formed blood vessels are fragile and prone to leaking fluid or blood, which can damage retinal tissues and lead to vision distortion or loss.
The main treatment options for choroidal neovascularization include anti-angiogenic therapy, laser photocoagulation, photodynamic therapy, verteporfin sodium, ranibizumab, bevacizumab, aflibercept, and pegaptanib sodium. Anti-angiogenic therapy works by inhibiting the formation of new blood vessels (angiogenesis), helping to prevent the growth of abnormal blood vessels. These treatments are commonly used for specific conditions such as age-related macular degeneration (AMD), diabetic macular edema (DME), central serous chorioretinopathy (CSC), polypoidal choroidal vasculopathy (PCV), myopic macular degeneration (MMD), and other related conditions. The administration route may vary, including intravitreal, subconjunctival, periocular, or oral methods. These therapies are primarily administered in hospitals, ophthalmology clinics, and ambulatory surgical centers.
The choroidal neovascularization market research report is one of a series of new reports from The Business Research Company that provides choroidal neovascularization market statistics, including the choroidal neovascularization industry global market size, regional shares, competitors with the choroidal neovascularization market share, detailed choroidal neovascularization market segments, market trends, and opportunities, and any further data you may need to thrive in the choroidal neovascularization industry. This choroidal neovascularization market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The choroidal neovascularization market size has grown strongly in recent years. It will grow from $3.37 billion in 2024 to $3.61 billion in 2025 at a compound annual growth rate (CAGR) of 8.1%. The growth during the historic period can be attributed to factors such as the increasing prevalence of sedentary lifestyle diseases, the rising incidence of age-related macular degeneration, a higher occurrence of retinal illnesses, a growing elderly population, escalating eye care costs, and expanding education and screening initiatives.
The choroidal neovascularization market size is expected to see strong growth in the next few years. It will grow to $5.64 billion in 2029 at a compound annual growth rate (CAGR) of 7.7%. The growth during the forecast period can be attributed to factors such as increasing patient awareness, the growing adoption of optical coherence tomography angiography, rising demand for minimally invasive procedures, favorable reimbursement policies, and a growing geriatric population. Key trends in this period include the emergence of intravitreal anti-vascular endothelial growth factor (VEGF) therapies, new gene treatments, gene therapy approaches, the adoption of telemedicine, the development of combination therapies, and personalized treatment strategies.
The increasing prevalence of age-related macular degeneration (AMD) is expected to drive the growth of the choroidal neovascularization (CNV) market in the future. AMD is an eye condition that gradually damages the macula, resulting in central vision loss, particularly among older adults. The rising prevalence of AMD is attributed to factors such as an aging population, increased life expectancy, lifestyle changes, genetic influences, and increased exposure to environmental risks. CNV plays a significant role in wet AMD, where abnormal blood vessel growth beneath the retina leads to vision deterioration. Advanced treatments such as anti-VEGF therapy are used to manage CNV, slow the progression of AMD, and help preserve central vision in affected individuals. For example, in September 2022, the National Institutes of Health projected that by 2040, AMD cases may reach 300 million, and by 2050, 5.4 million Americans could be affected. Therefore, the rising prevalence of AMD is driving the growth of the CNV market.
Leading companies in the CNV market are focusing on developing innovative treatments, such as photodynamic therapy (PDT), to provide eye care professionals with more precise and effective options that enhance patient outcomes and treatment delivery. PDT uses a photosensitizing agent activated by light to target and destroy abnormal or cancerous cells. For instance, in February 2023, Bausch & Lomb, a Canada-based healthcare company, and Modulight, a Finland-based biomedical company, announced the approval of the ML6710i photodynamic laser by the U.S. Food and Drug Administration. This therapy is used in conjunction with Bausch + Lomb's VISUDYNE therapy to treat CNV caused by AMD. The advanced, mobile ophthalmic laser offers a targeted approach to treating abnormal blood vessels in the eye, helping to prevent further disease progression and preserve vision.
In March 2024, Sandoz Group AG, a Switzerland-based pharmaceutical company, acquired the CIMERLI business from Coherus for $170 million. With this acquisition, Sandoz aims to expand its portfolio in the ophthalmic sector, strengthening its ability to offer innovative treatments for retinal diseases, such as AMD. Coherus BioSciences, a U.S.-based biopharmaceutical company, focuses on the research and development of treatments for diseases such as CNV.
Major players in the choroidal neovascularization market are Pfizer Inc., Roche Holding AG, AbbVie Inc., Bayer Aktiengesellschaft, Novartis AG, Teva Pharmaceutical Industries Limited, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Biogen Inc., Chugai Pharmaceutical Co. Ltd., Alcon Inc., Genentech Inc., Bausch + Lomb Incorporated, Samsung Bioepis Co. Ltd., Santen Pharmaceutical Co. Ltd., Apellis Pharmaceuticals Inc., Kodiak Sciences Inc., Xbrane Biopharma AB, Allergan Inc., Adverum Biotechnologies Inc., Clearside Biomedical Inc., Sylentis S.A.
North America was the largest region in the choroidal neovascularization market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in choroidal neovascularization report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the choroidal neovascularization market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The choroidal neovascularization market consists of revenues earned by entities by providing services such as diagnostic services, therapeutic services, and follow-up and monitoring services. The market value includes the value of related goods sold by the service provider or included within the service offering. The choroidal neovascularization market also includes sales of injections, therapy agents, and surgical & laser devices. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Choroidal Neovascularization Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on choroidal neovascularization market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for choroidal neovascularization ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The choroidal neovascularization market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Treatment Type: Anti-Angiogenic Therapy; Laser Photocoagulation; Photodynamic Therapy; Verteporfin Sodium; Ranibizumab; Bevacizumab; Aflibercept; Pegaptanib Sodium
- 2) By Indication: Age-Related Macular Degeneration (AMD); Diabetic Macular Edema (DME); Central Serous Chorioretinopathy (CSC); Polypoidal Choroidal Vasculopathy (PCV); Myopic Macular Degeneration (MMD); Other Indications
- 3) By Route Of Administration: Intravitreal; Subconjunctival; Periocular; Oral
- 4) By End User: Hospitals; Ophthalmology Clinics; Ambulatory Surgical Centers; Research Centers
- Subsegments:
- 1) By Anti-Angiogenic Therapy (Anti-VEGF Therapy): Ranibizumab; Bevacizumab; Aflibercept; Pegaptanib Sodium
- 2) By Laser Photocoagulation: Thermal Laser Photocoagulation; MicroPulse Laser Therapy
- 3) By Photodynamic Therapy (PDT): Standard PDT; Low-Fluence PDT; Half-Dose PDT
- 4) By Verteporfin Sodium: Intravenous Administration; Combination Therapy With Anti-VEGF
- 5) By Ranibizumab: Monthly Dosing; As-Needed Dosing; Treat-and-Extend Regimen
- 6) By Bevacizumab: Off-Label Use; Compounded Intravitreal Injections
- 7) By Aflibercept: Fixed-Dosing Regimen; Treat-and-Extend Regimen
- 8) By Pegaptanib Sodium: Monotherapy; Combination Therapy
- Companies Mentioned: Pfizer Inc.; Roche Holding AG; AbbVie Inc.; Bayer Aktiengesellschaft; Novartis AG
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Choroidal Neovascularization Market Characteristics
3. Choroidal Neovascularization Market Trends And Strategies
4. Choroidal Neovascularization Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market
5. Global Choroidal Neovascularization Growth Analysis And Strategic Analysis Framework
- 5.1. Global Choroidal Neovascularization PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Choroidal Neovascularization Market Growth Rate Analysis
- 5.4. Global Choroidal Neovascularization Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Choroidal Neovascularization Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Choroidal Neovascularization Total Addressable Market (TAM)
6. Choroidal Neovascularization Market Segmentation
- 6.1. Global Choroidal Neovascularization Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Anti-Angiogenic Therapy
- Laser Photocoagulation
- Photodynamic Therapy
- Verteporfin Sodium
- Ranibizumab
- Bevacizumab
- Aflibercept
- Pegaptanib Sodium
- 6.2. Global Choroidal Neovascularization Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Age-Related Macular Degeneration (AMD)
- Diabetic Macular Edema (DME)
- Central Serous Chorioretinopathy (CSC)
- Polypoidal Choroidal Vasculopathy (PCV)
- Myopic Macular Degeneration (MMD)
- Other Indications
- 6.3. Global Choroidal Neovascularization Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Intravitreal
- Subconjunctival
- Periocular
- Oral
- 6.4. Global Choroidal Neovascularization Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospitals
- Ophthalmology Clinics
- Ambulatory Surgical Centers
- Research Centers
- 6.5. Global Choroidal Neovascularization Market, Sub-Segmentation Of Anti-Angiogenic Therapy (Anti-VEGF Therapy), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Ranibizumab
- Bevacizumab
- Aflibercept
- Pegaptanib Sodium
- 6.6. Global Choroidal Neovascularization Market, Sub-Segmentation Of Laser Photocoagulation, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Thermal Laser Photocoagulation
- MicroPulse Laser Therapy
- 6.7. Global Choroidal Neovascularization Market, Sub-Segmentation Of Photodynamic Therapy (PDT), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Standard PDT
- Low-Fluence PDT
- Half-Dose PDT
- 6.8. Global Choroidal Neovascularization Market, Sub-Segmentation Of Verteporfin Sodium, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Intravenous Administration
- Combination Therapy With Anti-VEGF
- 6.9. Global Choroidal Neovascularization Market, Sub-Segmentation Of Ranibizumab, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Monthly Dosing
- As-Needed Dosing
- Treat-and-Extend Regimen
- 6.10. Global Choroidal Neovascularization Market, Sub-Segmentation Of Bevacizumab, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Off-Label Use
- Compounded Intravitreal Injections
- 6.11. Global Choroidal Neovascularization Market, Sub-Segmentation Of Aflibercept, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Fixed-Dosing Regimen
- Treat-and-Extend Regimen
- 6.12. Global Choroidal Neovascularization Market, Sub-Segmentation Of Pegaptanib Sodium, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Monotherapy
- Combination Therapy
7. Choroidal Neovascularization Market Regional And Country Analysis
- 7.1. Global Choroidal Neovascularization Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Choroidal Neovascularization Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Choroidal Neovascularization Market
- 8.1. Asia-Pacific Choroidal Neovascularization Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Choroidal Neovascularization Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Choroidal Neovascularization Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Choroidal Neovascularization Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Choroidal Neovascularization Market
- 9.1. China Choroidal Neovascularization Market Overview
- 9.2. China Choroidal Neovascularization Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Choroidal Neovascularization Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Choroidal Neovascularization Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Choroidal Neovascularization Market
- 10.1. India Choroidal Neovascularization Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Choroidal Neovascularization Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Choroidal Neovascularization Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Choroidal Neovascularization Market
- 11.1. Japan Choroidal Neovascularization Market Overview
- 11.2. Japan Choroidal Neovascularization Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Choroidal Neovascularization Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Choroidal Neovascularization Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Choroidal Neovascularization Market
- 12.1. Australia Choroidal Neovascularization Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Choroidal Neovascularization Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Choroidal Neovascularization Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Choroidal Neovascularization Market
- 13.1. Indonesia Choroidal Neovascularization Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Choroidal Neovascularization Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Choroidal Neovascularization Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Choroidal Neovascularization Market
- 14.1. South Korea Choroidal Neovascularization Market Overview
- 14.2. South Korea Choroidal Neovascularization Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Choroidal Neovascularization Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Choroidal Neovascularization Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Choroidal Neovascularization Market
- 15.1. Western Europe Choroidal Neovascularization Market Overview
- 15.2. Western Europe Choroidal Neovascularization Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Choroidal Neovascularization Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Choroidal Neovascularization Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Choroidal Neovascularization Market
- 16.1. UK Choroidal Neovascularization Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Choroidal Neovascularization Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Choroidal Neovascularization Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Choroidal Neovascularization Market
- 17.1. Germany Choroidal Neovascularization Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Choroidal Neovascularization Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Choroidal Neovascularization Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Choroidal Neovascularization Market
- 18.1. France Choroidal Neovascularization Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Choroidal Neovascularization Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Choroidal Neovascularization Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Choroidal Neovascularization Market
- 19.1. Italy Choroidal Neovascularization Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Choroidal Neovascularization Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Choroidal Neovascularization Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Choroidal Neovascularization Market
- 20.1. Spain Choroidal Neovascularization Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Choroidal Neovascularization Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Choroidal Neovascularization Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Choroidal Neovascularization Market
- 21.1. Eastern Europe Choroidal Neovascularization Market Overview
- 21.2. Eastern Europe Choroidal Neovascularization Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Choroidal Neovascularization Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Choroidal Neovascularization Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Choroidal Neovascularization Market
- 22.1. Russia Choroidal Neovascularization Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Choroidal Neovascularization Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Choroidal Neovascularization Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Choroidal Neovascularization Market
- 23.1. North America Choroidal Neovascularization Market Overview
- 23.2. North America Choroidal Neovascularization Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Choroidal Neovascularization Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Choroidal Neovascularization Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Choroidal Neovascularization Market
- 24.1. USA Choroidal Neovascularization Market Overview
- 24.2. USA Choroidal Neovascularization Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Choroidal Neovascularization Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Choroidal Neovascularization Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Choroidal Neovascularization Market
- 25.1. Canada Choroidal Neovascularization Market Overview
- 25.2. Canada Choroidal Neovascularization Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Choroidal Neovascularization Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Choroidal Neovascularization Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Choroidal Neovascularization Market
- 26.1. South America Choroidal Neovascularization Market Overview
- 26.2. South America Choroidal Neovascularization Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Choroidal Neovascularization Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Choroidal Neovascularization Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Choroidal Neovascularization Market
- 27.1. Brazil Choroidal Neovascularization Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Choroidal Neovascularization Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Choroidal Neovascularization Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Choroidal Neovascularization Market
- 28.1. Middle East Choroidal Neovascularization Market Overview
- 28.2. Middle East Choroidal Neovascularization Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Choroidal Neovascularization Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Choroidal Neovascularization Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Choroidal Neovascularization Market
- 29.1. Africa Choroidal Neovascularization Market Overview
- 29.2. Africa Choroidal Neovascularization Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Choroidal Neovascularization Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Choroidal Neovascularization Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Choroidal Neovascularization Market Competitive Landscape And Company Profiles
- 30.1. Choroidal Neovascularization Market Competitive Landscape
- 30.2. Choroidal Neovascularization Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Bayer Aktiengesellschaft Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
31. Choroidal Neovascularization Market Other Major And Innovative Companies
- 31.1. Teva Pharmaceutical Industries Limited
- 31.2. Regeneron Pharmaceuticals Inc.
- 31.3. Astellas Pharma Inc.
- 31.4. Biogen Inc.
- 31.5. Chugai Pharmaceutical Co. Ltd.
- 31.6. Alcon Inc.
- 31.7. Genentech Inc.
- 31.8. Bausch + Lomb Incorporated
- 31.9. Samsung Bioepis Co. Ltd.
- 31.10. Santen Pharmaceutical Co. Ltd.
- 31.11. Apellis Pharmaceuticals Inc.
- 31.12. Kodiak Sciences Inc.
- 31.13. Xbrane Biopharma AB
- 31.14. Allergan Inc.
- 31.15. Adverum Biotechnologies Inc.
32. Global Choroidal Neovascularization Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Choroidal Neovascularization Market
34. Recent Developments In The Choroidal Neovascularization Market
35. Choroidal Neovascularization Market High Potential Countries, Segments and Strategies
- 35.1 Choroidal Neovascularization Market In 2029 - Countries Offering Most New Opportunities
- 35.2 Choroidal Neovascularization Market In 2029 - Segments Offering Most New Opportunities
- 35.3 Choroidal Neovascularization Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
